Program
GZR33
A development code. Also written as “GZR33 Injection” and “GZR-33”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1, led by Gan & Lee Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gan & Lee Pharmaceuticals | 54 open or running | phase 3since Apr 8, 2026 | Aug 8, 2024 | Feb 2, 2027phase 1 · NCT07918898 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 8, 2024First study: phase 1 study in Healthy SubjectsFirst studyNCT06548932 · 52 enrolled · China
- Aug 14, 2024Phase 2 study in Diabetes Mellitus, Type 2NCT06558708 · 60 planned · China
- Nov 17, 2025Phase 1 study in Type 1 Diabetes MellitisNCT07242664 · 12 planned · Germany
- Apr 8, 2026Phase 3 study in Diabetes Mellitus, Type 2Phase 3 reachedNCT07527078 · 350 planned · China
- Oct 27, 2026Phase 1 study in Healthy ParticipantsNCT07918898 · 26 planned
Ahead
- Feb 2, 2027Primary completion: phase 1 study in Healthy ParticipantsNCT07918898
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07918898Healthy Participants | 1 | Not yet recruiting | Feb 2, 2027 | 26 |
| NCT07527078Diabetes Mellitus, Type 2 · China | 3 | Recruiting | Apr 7, 2026 | 350 |
| NCT07242664Type 1 Diabetes Mellitis · Germany | 1 | Recruiting | Feb 28, 2026 | 12 |
| NCT06558708Diabetes Mellitus, Type 2 · China | 2 | Recruiting | Dec 2024 | 60 |
| NCT06548932Healthy Subjects · China | 1 | Completed | Feb 24, 2023 | 52 |
How it is read
Names in the registry
- “GZR33 Injection”, 4 entries
- “GZR-33”, 1 entry
Codes read as this program: GZR33.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 2 studies
- Diabetes Mellitus, Type 1, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.